Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination of two agents**: **enoxaparin sodium** (a low-molecular-weight heparin anticoagulant) and **andexanet alfa** (a recombinant modified human factor Xa decoy protein). Enoxaparin sodium works by enhancing antithrombin-mediated inhibition of coagulation factors (mainly factor Xa and to a lesser degree factor IIa/thrombin), exerting its anticoagulant effect. Andexanet alfa is used as an antidote/reversal agent for bleeding due to factor Xa inhibitors, including enoxaparin. It acts as a factor Xa decoy, binding and sequestering factor Xa inhibitors, rapidly neutralizing their anticoagulant activity and restoring coagulation in cases of major or uncontrolled bleeding[2][4][5]. This combination is not a branded coformulation but refers to the administration of both drugs, usually with andexanet alfa given to reverse life-threatening anticoagulation from enoxaparin[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on enoxaparin sodium + andexanet alfa.